Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.

Yang, Hailei; Geng, Aizhi; Wang, Zhenfeng; Wu, Chuanzhong

Yang, Hailei; Geng, Aizhi; Wang, Zhenfeng; Wu, Chuanzhong.

Affiliation

Yang H; Department of Gynecology, The Second People's Hospital of Liaocheng, Linqing, 252600, China.
Geng A; Department of Gynecology, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Linqing, 252600, China.
Wang Z; Department of Gynecology, The Second People's Hospital of Liaocheng, Linqing, 252600, China.
Wu C; Department of Gynecology, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Linqing, 252600, China.

J Obstet Gynaecol Res ; 49(6): 1611-1619, 2023 Jun.

Article in En | MEDLINE | ID: mdl-36988159

Subject(s)

Ovarian Neoplasms; Paclitaxel; Humans; Female; Paclitaxel/adverse effects; Cohort Studies; Retrospective Studies; Neoplasm Recurrence, Local/therapy; Carcinoma, Ovarian Epithelial/drug therapy; Doxorubicin/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Key words

apatinib; recurrent platinum-resistant ovarian cancer; safety; survival; treatment response

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Paclitaxel Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: J Obstet Gynaecol Res Journal subject: GINECOLOGIA / OBSTETRICIA Year: 2023 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google